Progress in Synthetic Hypericin Manufacturing
Active Ingredient Manufacturing Transfer to the U.S. Complete
Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on addressing unmet medical needs in rare diseases, has successfully completed the transfer of its synthetic hypericin active ingredient manufacturing process under its partnership agreement with Sterling Pharma Solutions. This significant achievement marks the transition of production from Europe to the U.S., facilitating the optimization and implementation of a scalable production process for this crucial active ingredient. Synthetic hypericin is a key component in formulations such as HyBryte™ and SGX302, which are being developed for treating conditions like cutaneous T-cell lymphoma (CTCL) and psoriasis.
Successful Collaboration for Clinical Advancements
Christopher J. Schaber, PhD, President and CEO of Soligenix, expressed satisfaction with the successful production of larger quantities of cGMP synthetic hypericin. He emphasized the importance of ongoing collaboration with Sterling Pharma Solutions to refine the manufacturing process and reduce costs. The intent is to further advance the clinical programs related to topical hypericin, particularly HyBryte™, which offers promising outcomes for early-stage CTCL treatment.
Expertise at Sterling Pharma Solutions
Adam Kujath, Site Head of Sterling Pharma Solutions' Germantown facility, highlighted the value of their expertise in active pharmaceutical ingredient manufacturing. Sterling's innovative solutions, including continuous flow chemistry, are anticipated to enhance the efficiency and output of the Soligenix program, ultimately aiming for a commercial supply agreement.
About HyBryte™ and Its Significance
HyBryte™, also known as SGX301, represents a groundbreaking first-in-class photodynamic therapy utilizing safe, visible light for activation. The unique mechanism of synthetic hypericin allows targeted treatment of skin lesions related to CTCL. When activated by visible light, this therapy specifically targets malignant T-cells while minimizing the risk of secondary malignancies often associated with traditional phototherapy methods reliant on UV exposure. Moreover, initial clinical studies have showcased the efficacy of HyBryte™ in significantly reducing skin lesions in patients with CTCL.
Clinical Study Outcomes and Safety Profile
The published results from the Phase 3 FLASH trial involved 169 patients with early-stage CTCL, showcasing a substantial response rate in those treated with HyBryte™ compared to placebo. The therapy was well tolerated throughout the treatment cycles, reaffirming its safety profile, which is crucial considering the severe side effects linked to conventional treatments.
Future Directions for HyBryte™
In light of the encouraging results from the first Phase 3 study, the FDA and the European Medicines Agency (EMA) have requested a second confirmatory Phase 3 trial named FLASH2. This trial aims to enroll 80 subjects and will replicate the successful components of the initial study, including an extended treatment duration of 18 continuous weeks. This approach is designed to assess HyBryte's™ performance in a more realistic treatment setting. Furthermore, ongoing discussions with the FDA underscore the importance of aligning study designs to expedite market approval for HyBryte™.
Significance of Ongoing Research and Development
Soligenix is committed to exploring additional treatment avenues for synthetic hypericin beyond CTCL, with the potential application for conditions like psoriasis and other inflammatory diseases. This commitment is further supported by substantial grant funding aimed at advancing research initiatives. The prospect of HyBryte™ represents a critical advancement in the search for effective and safer treatments for patients with cutaneous T-cell lymphoma.
Understanding Cutaneous T-Cell Lymphoma (CTCL)
CTCL is a rare subset of non-Hodgkin's lymphoma, characterized by malignant T-cell proliferation in the skin. Patients with this condition often face significant challenges, as existing treatments may provide limited ease without guaranteed remission. With an estimated 31,000 individuals in the U.S. diagnosed with CTCL, the need for innovative therapies like HyBryte™ has never been more pressing. Currently, there is no established cure for CTCL, heightening the urgency for effective therapeutic options.
About Soligenix, Inc.
Soligenix is dedicated to aligning its operations with market needs by developing and commercializing therapeutics aimed at rare diseases. Focused on HyBryte™ for cutaneous T-cell lymphoma, the company is on a path to seek regulatory approvals post the second Phase 3 study completion. Additionally, Soligenix pursues other innovative therapies within its Public Health Solutions segment, which includes vaccine candidates for infectious diseases, reflecting its commitment to addressing significant health challenges.
Frequently Asked Questions
What is synthetic hypericin?
Synthetic hypericin is a potent photosensitizer used for treating skin lesions, particularly in cutaneous T-cell lymphoma.
How does HyBryte™ work?
HyBryte™ utilizes safe, visible light to activate synthetic hypericin, targeting malignant T-cells in the skin without causing DNA damage.
What are the outcomes of clinical studies on HyBryte™?
Clinical studies have demonstrated a significant reduction in lesions for CTCL patients treated with HyBryte™, showing its efficacy and safety profile.
What is the significance of the upcoming FLASH2 trial?
The FLASH2 trial aims to further investigate the efficacy of HyBryte™ following positive results from the first Phase 3 trial, expanding its clinical validation.
How does Soligenix plan to expand its treatment offerings?
Soligenix is exploring applications of synthetic hypericin beyond CTCL, including its potential use in psoriasis and other inflammatory diseases.
